Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, shared a post on X:
“Many immunomodulators, including TLR3 and other toll like receptors, have dual inhibitory and stimulatory functions.
They are double-edged sword!”
“Toll-like receptor 3: a double-edged sword.”
Authors: Marvin L Hsieh, Daisuke Nishizaki, Jacob J Adashek, Shumei Kato and Razelle Kurzrock
